GLSH · Gelesis Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Revenue | $11.19M | - | - |
| Cost of Revenue | $9.98M | - | - |
| Gross Profit | $1.20M | - | - |
| R&D | $12.87M | - | - |
| SG&A | $71.04M | - | - |
| Total Operating Expenses | $147.57M | $20.67M | $2.43M |
| D&A | $1.52M | - | - |
| Operating Income | ($121.81M) | ($20.67M) | ($2.43M) |
| Interest Expense | $1.36M | - | - |
| Income Tax | $480.0K | $0 | - |
| Net Income | ($55.78M) | ($12.90M) | ($2.22M) |
| EPS - Basic | ($32.89) | - | - |
| EPS - Diluted | ($32.89) | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Cash & Equivalents | $7.41M | $221.2K | $491.8K |
| Accounts Receivable | $1.23M | - | - |
| Inventory | $6.87M | - | - |
| Accounts Payable | $4.13M | - | - |
| Current Assets | $23.50M | $234.7K | $557.8K |
| Total Assets | $103.32M | $276.44M | $276.77M |
| Current Liabilities | $78.35M | - | - |
| Long-term Debt | - | - | - |
| Total Liabilities | $115.79M | $53.97M | $11.29M |
| Stockholders' Equity | ($25.06M) | ($53.52M) | $0 |
| Retained Earnings | ($322.63M) | ($53.52M) | ($672.9K) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Operating Cash Flow | ($77.73M) | ($446.6K) | ($861.3K) |
| Investing Cash Flow | ($9.12M) | $176.0K | ($276.00M) |
| Financing Cash Flow | $32.53M | - | $277.35M |
| CapEx | $19.92M | - | - |
| Free Cash Flow | ($97.64M) | - | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Profitability | |||
| Gross margin | 10.7% | - | - |
| Operating margin | -1089.0% | - | - |
| EBITDA margin | -1075.4% | - | - |
| Net margin | -498.7% | - | - |
| Free cash flow margin | -873.0% | - | - |
| FCF / Net income | 1.75 | - | - |
| R&D / Revenue | 115.0% | - | - |
| SG&A / Revenue | 635.1% | - | - |
| Effective tax rate | - | - | - |
| Return on assets | -54.0% | -4.7% | -0.8% |
| Return on equity | 222.6% | 24.1% | - |
| Return on invested capital | - | - | - |
| Liquidity | |||
| Current ratio | 0.30 | - | - |
| Quick ratio | 0.21 | - | - |
| Cash ratio | 0.09 | - | - |
| Leverage | |||
| Debt / Equity | - | - | - |
| Debt / Assets | - | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | -89.3x | - | - |
| Equity multiplier | -4.12 | -5.16 | - |
| Liabilities / Assets | 1.12 | 0.20 | 0.04 |
| Efficiency | |||
| Asset turnover | 0.11 | - | - |
| Inventory turnover | 1.45 | - | - |
| Days sales outstanding | 40d | - | - |
| Days inventory outstanding | 251d | - | - |
| Days payable outstanding | 151d | - | - |
| Cash conversion cycle | 140d | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | - | - | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | - | - | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | -489.2% | -752.1% | - |
| Net income growth (YoY) | -332.5% | -481.8% | - |
| EPS growth (YoY) | - | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | - | - | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | 53.2% | - | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-6.67
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
0/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing GELESIS HOLDINGS against the 5 most active filers in the same SIC group.